# Spyre Therapeutics Deprioritizes Rheumatoid Arthritis Development After Weak Phase 2 TL1A Data


## Key Takeaways

- Spyre Therapeutics has deprioritized its anti-TL1A antibody, SPY072, for monotherapy development in rheumatoid arthritis (RA) due to Phase 2 clinical trial data that did not meet efficacy expectations.
- The TL1A pathway, a target for SPY072, is implicated in inflammatory signaling and is a focus for drug development in autoimmune diseases like RA and inflammatory bowel disease (IBD).
- This decision highlights the significant challenge in translating preclinical efficacy of novel therapeutic targets into demonstrable clinical benefit for RA patients, a highly competitive therapeutic landscape.
- The deprioritization allows Spyre Therapeutics to reallocate resources to other pipeline assets or indications where supporting data may be more robust, potentially for SPY072 in combination therapy or other autoimmune conditions.

---

Spyre Therapeutics has decided to deprioritize monotherapy development of its anti-TL1A antibody SPY072 in rheumatoid arthritis after Phase 2 data fell short of expectations. The biotech’s rheumatoid arthritis plan has been toppled by the subpar results.

The company is now shifting its focus away from SPY072 as a monotherapy for the indication, though the full scope of the strategic pivot has not been detailed. The Phase 2 data were the primary reason for the change in priority.

Spyre’s antibody targets TL1A, a protein involved in inflammatory signaling. The TL1A pathway has been a focus of drug development in autoimmune diseases, including inflammatory bowel disease and rheumatoid arthritis. Several biotech and pharmaceutical companies are pursuing TL1A inhibitors.

The setback for Spyre underscores the challenge of translating preclinical promise into clinical efficacy in rheumatoid arthritis, a competitive therapeutic area with many approved and emerging treatments. Deprioritizing the program allows Spyre to allocate resources to other pipeline candidates or indications where the data may be more supportive.

Source: [original report](https://www.fiercebiotech.com/biotech/spyres-rheumatoid-arthritis-plan-toppled-subpar-tl1a-data)